Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 34 | SFEBES2014 | Next issue

Society for Endocrinology BES 2014

ea0034oc6.1 | Clinical | SFEBES2014

Adverse outcome in glucocorticoid induced adrenal suppression; an analysis of short synacthen tests in 2782 patients

Chapman Matthew , Argese Nicola , Mani Dhanasekaran , Dabhi Vijay , Boot Christopher , Crowley Rachel , Stewart Paul , Tomlinson Jeremy

2–3% of the UK population are prescribed glucocorticoid (GC) therapy and their adverse effects contribute to a significant health burden. Suppression of endogenous GC secretion is a recognized complication of therapy, but the magnitude of the problem, together with its clinical consequences have not been determined. We conducted a retrospective study across all specialties in a large secondary–tertiary care center identifying 2782 patients who underwent 3666 250 &#95...

ea0034oc6.2 | Clinical | SFEBES2014

Localising parathyroid adenomas: which imaging modality is best? Pre-operative localisation studies in patients with primary hyperparathyroidism: a large audit in a London tertiary centre

Lewis Danielle , Hubbard J , Moonim M , Dasgupta D , Thomas S , Powrie J K , Carroll P V , McGowan B M

Parathyroidectomy is the only definitive cure for primary hyperparathyroidism (PHPT). The standard for pre-operative localisation of parathyroid pathology at our institution is both a (99m)Tc-sestamibi SPECT/CT (sestamibi) and neck ultrasound scan (USS). The aim of this audit was to assess the accuracy of this standard pre-operative imaging.Methods: Retrospective data was gathered from all parathyroidectomies performed at St Thomas’ Hospital between...

ea0034oc6.3 | Clinical | SFEBES2014

Sirolimus therapy for a patient with segmental overgrowth due to a mosaic activating mutation in phosphatidylinositol-3-kinase

Parker Victoria , Huson Susan , Isaac Iona , Harris Julie , Payne Felicity , Lindhurst Marjorie , Barroso Ines , Biesecker Leslie , Semple Robert

Background: Phosphatidylinositol-3-kinase (PI3K) is a critical mediator of insulin action, and influences cellular growth, survival and metabolism. Recently, somatic gain-of-function mutations in the p110α catalytic subunit of PI3K (PIK3CA) have been found in a spectrum of overgrowth disorders, outlining the possibility of treatment with inhibitors of the PI3K–AKT–mTOR pathway.Methods/Results: A 37-year-old female, presented with life-long...

ea0034oc6.4 | Clinical | SFEBES2014

Reduced cognitive performance and altered white matter microstructure in young insulin-resistant women with polycystic ovary syndrome

Udiawar Maneesh , Berlot Rok , O'Sullivan Michael , Rees Aled

Background: Metabolic disorders such as type 2 diabetes are risk factors for the development of dementia. In addition to vascular dysfunction, insulin resistance may be important since altered insulin sensitivity is associated with changes in neurogenesis. Polycystic ovary syndrome (PCOS) is a disorder characterised by insulin resistance. Little is known about the impact of metabolic abnormalities on brain structure and function in younger adults.Objecti...

ea0034oc6.5 | Clinical | SFEBES2014

Effectiveness of metyrapone in 195 patients with Cushing's syndrome

Daniel Eleni , Aylwin Simon , Mustafa Omar , Ball Steve , Munir Atif , Boelaert Kristien , Chortis Vasileios , Cuthbertson Daniel J , Daousi Christina , Rajeev Surya , Davis Julian , Cheer Kelly , Drake William , Gunganah Kirun , Grossman Ashley , Gurnell Mark , Powlson Andrew , Karavitaki Niki , Huquet Isabel , Kearney Tara , Mohit Kumar , Meeran Karim , Hill Neil , Rees Aled , Trainer Peter J , Lansdown Andrew J , Minder Anna-Elisabeth H , Newell-Price John

Background: Metyrapone is widely used in the UK for the control of cortisol excess in Cushing’s syndrome, but its use is not standardised. There are a few reports published on metyrapone use, mostly containing small patient numbers.Method: A retrospective survey was conducted across 13 tertiary centres. Using a standardised proforma, extensive data including monitoring and safety information were collected for patients with Cushing’s syndrome o...

ea0034oc6.6 | Clinical | SFEBES2014

11C-methionine PET--CT co-registered with volume MRI: a novel adjunctive imaging modality to aid diagnosis and management in patients with pituitary adenomas

Koulouri Olympia , Kandasamy Narayanan , Powlson Andrew , Moran Carla , Cheow Heok , Antoun Nagui , Levy Miles , Hoole Andrew , Chatterjee Krishna , Donnelly Neil , Mannion Richard , Burnet Neil , Pickard John , Gurnell Mark

Although MRI remains the investigation of choice for pituitary imaging, it does not provide information about ‘functionality’ of lesions (e.g. residual adenoma vs post-surgical scar tissue) and cannot reliably identify all microadenomas.We hypothesised that i) imaging with the PET ligand 11C-methionine, which is taken up at sites of peptide/protein synthesis, would permit more reliable identification of functioning pituitary adenoma ...